Pfizer Stock News

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants.

Eli Lilly's GLP-1 drug is now the world's best-selling drug. Novo Nordisk is struggling with declining market share.

Pfizer's sales and profits came in better than expected for the third quarter. The stock, however, remains down for the year.

Pfizer Inc. ( PFE ) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Jeff Legos Johanna Bendell - Chief Development Officer of Oncology Arati Rao Conference Call Participants Steve Scala - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equit...

Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulato...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration.

The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.

In September, we (my wife and I) received a dividend income total of $5,342.09. Our dividend income went up almost $1,000 from last year. We had more stocks increase last month, but the increases this month provided much more growth to the forward passive income stream.